Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunic gets a "positive surprise" from lead asset trial

By: TheNewswire.com

Immunic Inc (NASDAQ: IMUX) CEO Dr. Daniel Vitt speaks to Proactive following the release of data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset vidofludimus calcium (IMU-838) in patients with moderate-to-severe ulcerative colitis (UC).

Vitt describes it as "wonderful data" that came as a "positive surprise."

Contact Details

Proactive United States

Proactive United States

+1 347-449-0879

action@proactiveinvestors.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  205.29
+4.14 (2.06%)
AAPL  265.04
+1.16 (0.44%)
AMD  201.51
-1.57 (-0.77%)
BAC  53.30
+0.56 (1.06%)
GOOG  304.31
+1.49 (0.49%)
META  639.57
+0.28 (0.04%)
MSFT  400.38
+3.52 (0.89%)
NVDA  188.50
+3.53 (1.91%)
ORCL  156.22
+2.25 (1.46%)
TSLA  413.11
+2.48 (0.60%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.